Cancer risk in patients hospitalized with polymyalgia rheumatica and giant cell arteritis: a follow-up study in Sweden

被引:62
|
作者
Ji, Jianguang [1 ]
Liu, Xiangdong
Sundquist, Kristina [2 ]
Sundquist, Jan [3 ]
Hemminki, Kari [4 ]
机构
[1] Lund Univ, Ctr Primary Hlth Care Res, CRC, UMAS, S-20502 Malmo, Sweden
[2] Karolinska Inst, Ctr Family & Community Med, Stockholm, Sweden
[3] Stanford Univ, Sch Med, Stanford Prevent Res Ctr, Stanford, CA 94305 USA
[4] German Canc Res Ctr, Div Mol Genet Epidemiol, Heidelberg, Germany
关键词
Cancer; Polymyalgia rheumatica; Giant cell arteritis; National databases; TEMPORAL ARTERITIS; EPIDEMIOLOGY;
D O I
10.1093/rheumatology/keq040
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objectives. Studies reporting cancer risk after PMR and GCA are few, but it remains an issue of both concern and controversy. We examined the overall and specific cancer risks among Swedish subjects following hospitalization for these diseases. Methods. PMR and GCA patients were identified from the Swedish Hospital Discharge Register and by linking them with the Cancer Registry. Follow-up of patients was carried out from the last hospitalization through year 2006. Standardized incidence ratios (SIRs) were calculated in these patients compared with subjects without the diseases. Results. A total of 35 918 patients were hospitalized for PMR and GCA during the years 1965-2006; the hospitalization rate increased towards late age. A total of 3941 patients developed subsequent cancer, giving an overall SIR of 1.19; and for cancer diagnosed later than 1 year of follow-up, the SIR was 1.06. A significant excess was noted for skin (squamous cell carcinoma and melanoma), stomach, lung, prostate, kidney, nervous system and endocrine gland tumours, and additionally for non-Hodgkin's lymphoma, myeloma and leukaemia. Decreased risk was noted for endometrial cancer. Conclusions. Patients hospitalized for PMR and GCA had a marginally increased risk of cancer, with the highest risk noted for the first year after hospitalization. However, for specific cancers, such as skin cancer and leukaemia, the increases were still significant for patients diagnosed later than 1 year after hospitalization, suggesting that these could be true associations, but the mechanisms remain to be established.
引用
收藏
页码:1158 / 1163
页数:6
相关论文
共 50 条
  • [1] Predictive Factors of Giant Cell Arteritis in Polymyalgia Rheumatica Patients
    Ramon, Andre
    Greigert, Helene
    Ornetti, Paul
    Maillefert, Jean-Francis
    Bonnotte, Bernard
    Samson, Maxime
    JOURNAL OF CLINICAL MEDICINE, 2022, 11 (24)
  • [2] Cancer risk in hospitalized sarcoidosis patients: a follow-up study in Sweden
    Ji, J.
    Shu, X.
    Li, X.
    Sundquist, K.
    Sundquist, J.
    Hemminki, K.
    ANNALS OF ONCOLOGY, 2009, 20 (06) : 1121 - 1126
  • [3] Giant Cell Arteritis and Polymyalgia Rheumatica: an Update
    Gonzalez-Gay, Miguel A.
    Pina, Trinitario
    CURRENT RHEUMATOLOGY REPORTS, 2015, 17 (02)
  • [4] Polymyalgia rheumatica and giant cell arteritis
    Patel, Martyn
    Forsyth, Duncan R.
    JOURNAL OF CLINICAL GERONTOLOGY & GERIATRICS, 2011, 2 (01) : 7 - 12
  • [5] Risk of malignancy in patients with giant cell arteritis and polymyalgia rheumatica: A systematic review and meta-analysis
    Ungprasert, Patompong
    Sanguankeo, Anawin
    Upala, Sikarin
    Knight, Eric L.
    SEMINARS IN ARTHRITIS AND RHEUMATISM, 2014, 44 (03) : 366 - 370
  • [6] Clinical presentation and treatment response in patients with polymyalgia rheumatica and giant cell arteritis during a 40-week follow-up
    Emamifar, Amir
    Hess, Soren
    Ellingsen, Torkell
    Gerke, Oke
    Farahani, Ziba Ahangarani
    Hansen, Per Syrak
    Hansen, Inger Marie Jensen
    Thye-Ronn, Peter
    RHEUMATOLOGY ADVANCES IN PRACTICE, 2021, 5 (03)
  • [7] Update on the Treatment of Giant Cell Arteritis and Polymyalgia Rheumatica
    El Chami, Sarah
    Springer, Jason M.
    MEDICAL CLINICS OF NORTH AMERICA, 2021, 105 (02) : 311 - 324
  • [8] Update on the Treatment of Giant Cell Arteritis and Polymyalgia Rheumatica
    El Chami, Sarah
    Springer, Jason M.
    RHEUMATIC DISEASE CLINICS OF NORTH AMERICA, 2022, 48 (02) : 493 - 506
  • [9] Glucocorticoids for Management of Polymyalgia Rheumatica and Giant Cell Arteritis
    Matteson, Eric L.
    Buttgereit, Frank
    Dejaco, Christian
    Dasgupta, Bhaskar
    RHEUMATIC DISEASE CLINICS OF NORTH AMERICA, 2016, 42 (01) : 75 - +
  • [10] Discontinuation of therapies in polymyalgia rheumatica and giant cell arteritis
    Muratore, F.
    Pipitone, N.
    Hunder, G. G.
    Salvarani, C.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2013, 31 (04) : S86 - S92